AN1 0.00% 0.8¢ anagenics limited

Ann: Agreement Signed for Sale of Lyramid Limited, page-263

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 384 Posts.
    lightbulb Created with Sketch. 727

    According to the European Patent Office, Cellmid holds various patents, or to be more precise various patent families, within two different groups. Some, we are informed, have been licensed to Lyramid. Others are held by Advangen. One of the latter relates to Midkine.

    Some details here -

    METHOD OF TREATMENT OR PREVENTION OF HAIR LOSS OR FOR THE ENHANCEMENT OF HAIR GROWTH

    Pat No: WO2011103624A1

    Applicant : ADVANGEN INTERNAT PTY LTD

    Inventors: Halasz Maria, Jones Darren, Sakuma Sadatoshi

    Abstract: The present application relates to use of a Midkine family protein for growing hair on a mammal, or in the manufacture of a medicament for growing hair on a mammal, especially for treatment or prevention of different forms of alopecia.

    Priority Date - 24 Feb 2010

    At an AGM a couple of years ago the question was asked as to whether or not this particular patent family would go to Lyramid or stay with Advangen. The reply was that it would stay with Advangen.

    So not "all midkine related patents" may in fact have been licensed to Lyramid.

    poorinvestor
 
watchlist Created with Sketch. Add AN1 (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.